The 20 subjects enrolled in a trial of the HSV-2 vaccine under development at Allied Healthcare's (ASX:AHZ) Coridon have all received two out of three planned doses. [ + ]

Genea Biocells has produced human skeletal muscle from stem cells, in a breakthrough technique with potential applications in the treatment of muscular dystrophies. [ + ]

The Melanoma Genome Project is well underway with sequencing data submitted to the International Cancer Genome Consortium repository and expectations this will be publicly available early next year. [ + ]

The Department of Health and Ageing has released draft technical guidelines for therapeutic services, open for consultation until 23 November 2013. [ + ]

Sydney-based uHealth will work with iSonea (ASX:ISN) to pursue more sales opportunities for the latter's asthma symptom monitoring device, AirSonea. [ + ]

The Centenary Institute's cytometry research program last night received the $1 million Ramaciotti Biomedical Research Award. As a result of the award, the Ramaciotti Centre for Human Systems Biology will be established. [ + ]

Innate Immunotherapeutics has moved its base from Auckland to Sydney as it prepares for Australian phase IIb trials of SPMS treatment candidate MIS416. [ + ]

The 2013 recipients of the biennial Ramaciotti Awards for biomedical research have been announced. [ + ]

Qiagen has launched the Empowered Genome Community - an initiative to help people who have had their genomes sequenced share, explore and interpret their data with researchers and each other. [ + ]

Results from a pilot trial of Ellex Medical Lasers' (ASX:ELX) Retinal Rejuvenation Therapy (2RT) suggest the treatment could act as an early intervention therapy for AMD. [ + ]

Brisbane's new biomedical research institute, Translational Research Institute, has been officially opened by the Governor-General, Her Excellency the Honourable Quentin Bryce. [ + ]

Austrade, in partnership with Australian federal and state government agencies, is organising the first Australian 'Innovation Week' in India and invites interested Australian companies to participate. While the entire program will run over three weeks, the life sciences component will run for one week, commencing 25 November 2013. [ + ]

A month after licensing MoxDuo IR for ANZ and Oceania to Aspen for $1.25m, QRxPharma (ASX:QRX) has expanded the deal to also cover South Africa. [ + ]

Biotech company Roche plans to invest 800 million Swiss francs within its global manufacturing network to increase production capabilities for its biologic medicines over the next five years. [ + ]

Genetic research reveals Barrett's oesophagus and oesophageal cancer are more closely linked than previously thought. [ + ]